UBE3A-ATS Antisense Oligonucleotides for Angelman Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Angelman Syndrome, caused by a deficiency of ubiquitin protein ligase E3A (UBE3A), are limited and often involve non-specific topoisomerase inhibitors that pose safety concerns due to DNA damage risks.
Innovation Solution
Development of oligomeric compounds, particularly modified oligonucleotides, to reduce UBE3A-ATS RNA expression and enhance paternal UBE3A RNA or protein expression, targeting specific neurogenetic disorders like Angelman Syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topoisomerase inhibitors are used to unsilence paternal UBE3A expression, then UBE3A expression is improved, but safety is worsened due to DNA damage risks
Solution Approach 1:
The patent extracts and targets specifically the UBE3A-ATS transcript using antisense oligonucleotides, separating the desired therapeutic effect (increasing UBE3A expression) from the harmful effects of non-specific topoisomerase inhibitors. By directly targeting only the antisense transcript rather than using broad-spectrum inhibitors, the method achieves selective modulation without causing DNA damage.
Solution Approach 2:
The patent introduces antisense oligonucleotides as intermediary molecules that mediate between the therapeutic goal (increasing UBE3A expression) and the genetic mechanism (silencing UBE3A-ATS). These oligonucleotides bind specifically to the UBE3A-ATS transcript and facilitate its degradation, serving as a precise intermediary that achieves the therapeutic effect without the harmful side effects of direct topoisomerase inhibition.
2Reliability
If non-specific topoisomerase inhibitors are used, then UBE3A expression may be increased, but treatment safety is worsened due to non-specific effects
Solution Approach 1:
The patent applies local quality by designing antisense oligonucleotides with specific sequence complementarity to the UBE3A-ATS transcript. The oligonucleotides are designed to bind only to the specific target sequence, creating a localized therapeutic effect at the transcript level rather than a non-specific systemic effect. This specificity is achieved through careful selection of the oligonucleotide sequence and its complementary binding to the antisense transcript.
3Ease of operation
If current symptomatic management therapies are used, then quality of life is maintained, but disease progression is not addressed
Solution Approach 1:
The patent applies preliminary action by targeting and degrading the UBE3A-ATS transcript before it can interfere with paternal UBE3A expression. By proactively silencing the antisense transcript at the transcriptional level, the method prevents the disease mechanism from acting rather than merely managing symptoms after they manifest. This preliminary intervention at the molecular level enables potential disease modification rather than just symptomatic management.
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurogenetic disorder. Such symptoms and hallmarks include developmental delays, ataxia, speech impairment, sleep problems, seizures, and EEG abnormalities. Such neurogenetic disorders include Angelman Syndrome.